On October 5, 2017, a Chicago jury ordered AbbVie, Inc. to pay more than $140 million to a Tennessee man, Jeffrey Konrad, who alleged that the Company misrepresented the risks of his testosterone replacement drug, AndroGel prescribed for Low-T, causing him to suffer a heart attack. This case is one of many in the testosterone...
Another Jury Finds AbbVie Misrepresented Risks of AndroGel & Awards $140 Million Verdict in Testosterone Heart Attack Lawsuit
